PTO 892 DEA/FCE 1994 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE NOTICE OF REFERENCES CITED						SERIAL NUMBER 09/769,223	Art 16	Unit 48	Attachment to Paper Number 12			
						APPLICANTS : Benveniste, R., E., et al.						
					U.S.	. PATEN	T DOCUMENTS					
*	DOCUMENT NUMBER			DAT	E		NAME(S)	CLASS	CLASS SUBCLAS		SS FILING DATE	
Ħ												
		a.										
FOREIGN PATENT DOCUMENTS												
*		DOCUMENT NO.		DATE		DUNTRY	NAME	CLASS		SUBCLASS		
												Щ
*		OTHER REFERENCES (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)										
	Hoth, D. F., et al., 1994, "HIV vaccine development: a progress report", Ann. Int. Med. 8(7):603-611.											
		Stott, J., and N. Almond, 1995, "Assessing animal models of AIDS", Nat. Med. 1(4):295-297.										
		Graham, B. S., and P. F. Wright, 1995, "Candidate AIDS vaccines", New Engl. J. Med. 333(20):1331-1339.										
		Haynes, B. F., et al., 1996, "Update on the issues of HIV vaccine development", Ann. Med. 28:39-41.										
		Haynes, B. F., 1996, "HIV vaccines: where we are and where we are going", Lancet 348:933-937.										
		Kent, S. J., et al., 1997, "Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection", J. Immunol. 158:807-815.										
		Lee, TH., 1997, "Acquired immunodeficiency disease vaccines: design and development", in AIDS: Biology, Diagnosis, Treatment and Prevention, fourth edition, DeVita, Jr., V. T., et al., eds., Lippincott-Raven Publishers, Philadelphia, PA, pp. 605-616.										
4		Letvin, N. L., 19	98, "Pr	rogres	s in t	he devel	opment of an HIV-1 vaccine	e", Scier	nce 28	0:187	5-18	80.
		Burton, D. R., and J. P. Moore, 1998, "Why do we not have an HIV vaccine and how can we make one?", Nat. Med. 4(5):495-498.										

DATE

\* A COPY OF THIS REFERENCE IS NOT BEING FURNISHED WITH THIS OFFICE ACTION. (SEE MPEP SECTION 707.05(a).

PAGE 1 OF 2

PTO 892 DEA/FCE 1994  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  NOTICE OF REFERENCES CITED					SERIAL NUMBER 09/769,223 APPLICANTS : Benveni	Art U 1648 ste, R. I	3	Attachment to Paper Number 12		
			U	.S. PATEN	T DOCUMENTS					
*	DOCUMENT NUMBER		DATE		NAME(S)		S SUBCLASS		FILING DATE	
FOREIGN PATENT DOCUMENTS										
*		DOCUMENT NO.	DATE	COUNTRY	NAME		CLASS	SUBG	CLASS	
		1								
*	OTHER REFERENCES (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)									
	Moore, J. P., and D. R. Burton, 1999, "HIV-1 neutralizing antibodies: how full is the bottle?", Nat. Med. 5(2):142-144.									
	•	Nathanson, N., and B. J. Mathieson, 2000, "Biological considerations in the development of a human immunodeficiency virus vaccine", J. Infect. Dis. 182:579-589.								
		Johnston, M. I., 2000, "The role of nonhuman primate models in AIDS vaccine development", Mol. Med. 6:267-270.								
		Bende, S., and M. I. Johnston, 2000, "Update: search for an AIDS vaccine", AIDS Reader, September, 526-538.								
		Feinberg, M. B., and J. P. Moore, 2002, "AIDS vaccine models: challenging challenge viruses", Nat. Med. 8(3):207-210.								
		Shearer, G. M., and M. Clerici, 1997, "Vaccine strategies: selective elicitation of cellular or humoral immunity?", TIBTECH 15:106-109.								
								<u></u>		

EXAMINER	DATE	* A COPY OF THIS REFERENCE IS NOT BEING FURNISHED WITH THIS OFFICE ACTION. (SEE MPEP SECTION 707.05(a).
Jeffrey S. Parkin, Ph.D.	03/05/03	PAGE 2 OF 2